Article
Oncology
Zhen Yang, Guangjun Shi
Summary: Patients with combined hepatocellular-cholangiocarcinoma (CHC) who underwent surgical intervention showed better long-term survival outcomes compared to non-surgical treatments. The overall survival rate of CHC patients was different from that of intrahepatic cholangiocarcinoma (ICC) patients before and after a 3-year follow-up.
Article
Gastroenterology & Hepatology
Maria Reig, Giuseppe Cabibbo
Summary: The potential impact of DAAs in BCLC-B/C stage patients with HCC is understudied, as HCC patients have been excluded from DAA trials. The decision on using DAAs should be made based on individual patient profiles.
JOURNAL OF HEPATOLOGY
(2021)
Review
Gastroenterology & Hepatology
Aurelie Beaufrere, Julien Calderaro, Valerie Paradis
Summary: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a tumor with both hepatocytic and biliary differentiation, whose diagnosis is primarily based on morphology and immunostaining, with a prognosis worse than hepatocellular carcinoma and treatment limited to surgery.
JOURNAL OF HEPATOLOGY
(2021)
Article
Oncology
Yanling Chen, Qing Lu, Weibin Zhang, Jiaying Cao, Yi Dong, Wenping Wang
Summary: A predictive nomogram based on clinical and ultrasound findings was established to distinguish combined hepatocellular-cholangiocarcinoma (CHC) from other subtypes of primary liver cancers (PLCs). The nomogram showed promising performance and clinical usefulness in differentiating CHC from hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Timo Alexander Auer, Federico Collettini, Laura Segger, Uwe Pelzer, Raphael Mohr, Felix Krenzien, Bernhard Gebauer, Dominik Geisel, Clarissa Hosse, Wenzel Schoening, Uli Fehrenbach
Summary: cHCC-CCA is a rare form of liver cancer that combines features of both hepatocellular and biliary tract cancer. There is currently no established interventional therapy for cHCC-CCA due to its rarity. This review aims to provide an overview of current radiologic interventions for CCA, review the existing literature, and explore the potential role of these interventions in the treatment of cHCC-CCA in the future.
Article
Medicine, Research & Experimental
Ru-Chen Xu, Fu Wang, Jia-Lei Sun, Weinire Abuduwaili, Guang-Cong Zhang, Zhi-Yong Liu, Tao-Tao Liu, Ling Dong, Xi-Zhong Shen, Ji-Min Zhu
Summary: In this study, a novel genetic cHCC-ICC mouse model was generated, providing insights into the molecular features and related signaling pathways of cHCC-ICC and identifying LAMB1 as a potential therapeutic target.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Jongman Kim, Dong-Jin Joo, Shin Hwang, Jeong-Moo Lee, Je-Ho Ryu, Yang-Won Nah, Dong-Sik Kim, Doo-Jin Kim, Young-Kyoung You, Hee-Chul Yu
Summary: Patients with combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CC) have poor outcomes and are not suitable for liver transplantation. This study compared the outcomes of living donor liver transplantation (LDLT) patients with hepatocellular carcinoma (HCC) and cHCC-CC, and identified risk factors for tumor recurrence and death in cHCC-CC patients after transplantation.
WORLD JOURNAL OF GASTROINTESTINAL SURGERY
(2023)
Review
Oncology
Laura Schwenk, Oliver Rohland, Aladdin Ali-Deeb, Felix Dondorf, Utz Settmacher, Falk Rauchfuss
Summary: Liver transplantation can be a possible curative therapy option for patients with combined hepatocellular carcinoma and sole intrahepatic cholangiocarcinoma. Our retrospective study found high overall survival and low recurrence rates in patients after liver transplantation for incidental intrahepatic cholangiocarcinoma or combined tumors. This suggests that liver transplantation could benefit patients with these types of liver cancer.
Article
Cell Biology
Yi Bai, Wen Tong, Fucun Xie, Liuyang Zhu, Hao Wu, Rui Shi, Lianjiang Wang, Long Yang, Zhisong Liu, Fei Miao, Qiang Zhao, Yaming Zhang
Summary: This study identified potential diagnostic DNA methylation sites for primary liver cancer (PLC) and distinguished hepatocellular carcinoma (HCC) from intrahepatic cholangiocarcinoma (ICC) through a model based on methylation analysis. Various methylation sites were pinpointed, and pathways related to HCC and ICC were elucidated. The methylator phenotype was found to correlate with clinical factors involved in tumor progression in both HCC and ICC.
Article
Gastroenterology & Hepatology
Xavier Adhoute, Olivia Pietri, Guillaume Penaranda, Thomas Wolf, Patrick Beaurain, Olivier Monnet, Arthur Laquiere, Justine Bonomini, Frederic Neumann, Olivier Levrel, Jean-Pascal Buono, Xavier Hanna, Paul Castellani, Herve Perrier, Marc Bourliere, Rodolphe Anty
Summary: This real-life study investigated the characteristics, treatment modalities, and prognoses of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA). The study found that HCC patients were more likely to have early-stage disease, while iCCA patients were more likely to be female, especially those without cirrhosis. Cirrhosis was prominent among HCC patients, but no difference in underlying liver disease among cirrhotic patients was found. The overall survival (OS) of HCC patients was 18.4 months, while that of iCCA patients was 7.0 months. Targetable molecular alterations were detected in 50% of the iCCA patients.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2023)
Review
Oncology
Haneyeh Shahbazian, Mohammad Mirza-Aghazadeh-Attari, Ali Borhani, Alireza Mohseni, Seyedeh Panid Madani, Golnoosh Ansari, Timothy M. Pawlik, Ihab R. Kamel
Summary: Hepatocellular carcinoma and intrahepatic cholangiocarcinoma are the two most common primary malignant tumors of the liver. This review discusses and outlines the similarities and variations in imaging characteristics that can help distinguish between these two primary tumors. Understanding the available imaging techniques would assist in differentiating these primary malignancies.
JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Surgery
Derar Jaradat, Georgios Bagias, Thomas Lorf, Yaman Tokat, Aiman Obed, Arzu Oezcelik
Summary: Patients with combined hepatocellular-cholangiocarcinoma undergoing liver transplantation have a higher perioperative mortality rate and a significant risk of disease recurrence, yet selected patients with early stage and real mixed HCC-CC lesions could potentially benefit from liver transplantation.
CLINICAL TRANSPLANTATION
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Venkata S. Katabathina, Lokesh Khanna, Venkateswar R. Surabhi, Marta Minervini, Krishna Shanbhogue, Anil K. Dasyam, Srinivasa R. Prasad
Summary: Hepatocellular adenomas, hepatocellular carcinomas, and intrahepatic cholangiocarcinomas are a highly heterogeneous group of liver tumors with diverse pathomolecular features and prognoses. The use of high-throughput gene sequencing techniques has allowed for the identification of distinct subtypes with varied clinicobiologic behaviors and imaging findings. The understanding of morphomolecular features of these tumors has important implications for diagnosis, treatment, and prognosis.
Article
Oncology
Ning Liu, Yaokun Wu, Yunyun Tao, Jing Zheng, Xiaohua Huang, Lin Yang, Xiaoming Zhang
Summary: This study investigated the efficacy of MRI radiomics in differentiating HCC from ICC. The results suggest that MRI-based radiomics may help noninvasively differentiate HCC from ICC, and the model integrating radiomics features and clinical risk factors showed a further improvement in performance.
Article
Gastroenterology & Hepatology
Laurence P. Diggs, Alexander M. Fagenson, Vijay Putatunda, Kwan Nang Lau, Miral S. Grandhi, Henry A. Pitt
Summary: Hepatectomy for ICC is associated with worse postoperative outcomes compared to CRLM and HCC, with higher mortality and morbidity rates.